GlassScriptPhysician profile
Mary Brulja
NPI 1548664626
$1,997.68
in general payments reported to CMS, 2019-2025
26 companies · $590 in 2025
The $590 reported for 2025 was more than what 84% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $474 · 2020: $126 · 2021: $22.70 · 2022: $117 · 2023: $446 · 2024: $223 · 2025: $590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,245 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,245.48 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $447.18 | 2019-2025 | Lo Loestrin Fe, Ubrelvy |
| Sumitomo Pharma America, INC. | $285.89 | 2023-2025 | Myfembree |
| Biogen, INC. | $251.00 | 2024-2025 | Zurzuvae |
| Bayer Healthcare Pharmaceuticals INC. | $120.97 | 2019-2025 | |
| Exeltis, USA INC. | $111.57 | 2019-2025 | Slynd |
| Coopersurgical, INC. | $106.19 | 2019-2025 | Paragard T 380a, Paragard T 380a, Endosee |
| Mayne Pharma Commercial LLC | $87.37 | 2024-2025 | |
| Millicent US INC | $84.48 | 2024-2025 | Femlyv, Intrarosa, Femring |
| Pfizer INC. | $60.20 | 2023 | |
| Angiodynamics, INC. | $50.55 | 2019 | |
| Organon LLC | $45.82 | 2023-2025 | Nexplanon |
| Hologic Sales and Service, LLC | $43.07 | 2019-2023 | Aptima, Thinprep 2000 Processor, Third Wave |
| Astellas Pharma US INC | $40.50 | 2023-2025 | Veozah |
| Allergan, INC. | $35.52 | 2019 | |
| Agile Therapeutics, INC. | $31.82 | 2022-2023 | Twirla |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $27.84 | 2019 | |
| Gynesonics, INC. | $22.44 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Medtronic, INC. | $22.33 | 2023 | Ligasure |
| Pharmacosmos Therapeutics INC. | $20.65 | 2024 | Monoferric |
| Daiichi Sankyo INC. | $20.46 | 2020 | |
| Amag Pharmaceuticals, INC. | $16.09 | 2019 | |
| Therapeuticsmd, INC. | $14.66 | 2022 | |
| Minerva Surgical, INC | $14.03 | 2019 | |
| Covidien LP | $12.52 | 2020 | |
| Merck Sharp & Dohme LLC | $12.35 | 2019 | |
| Scynexis, INC. | $12.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Brulja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.